Hypofractionated vs. Conventionally Fractionated Concurrent CRT for Unresectable Stage III NSCLC

Inclusion Criteria: * Male or female, aged 18 years to 75 years •.Histologically proven lung adenocarcinoma or squamous cell lung carcinoma of r Unresectable Stage III NSCLC(according to the TNM classification in theUnion for International Cancer Control (UICC) 7th ed.) * No prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKIs) treatment or other targeted therapy * No prior thoracic RT * No severe perioperative complications and expected postoperative lifespan ≥4 months * ECOG Performance Status 0-1 * Voluntarily participated in this study and signed the informed consent form by himself or his agent. Had good compliance with the study procedures, and can cooperate with the relevant examination, treatment and follow-up Exclusion Criteria: * Diagnosed with other prior or concurrent malignancies (neoplasm) except for basal cell carcinoma of the skin or carcinoma in situ of the cervix within the last 5 years * Patients with any severe or uncontrolled systematic disease including severe cardiovascular, liver, kidney, hematopoietic, metabolic disease, or uncontrolled active infection that would preclude study participation * Patients with positive mental disorder that would preclude study participation; * Contradictory to chest radiotherapy * Pregnant or nursing women * Concurrent other anti-cancer treatment * Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKIs) treatment or other targeted therapy